Featured Publications
Emerging Immunohistochemical Biomarkers for Myeloid Neoplasms.
Verma A, Xu ML. Emerging Immunohistochemical Biomarkers for Myeloid Neoplasms. Archives Of Pathology & Laboratory Medicine 2022, 147: 403-412. PMID: 35533352, DOI: 10.5858/arpa.2021-0558-ra.Peer-Reviewed Original ResearchConceptsMyeloid neoplasmsImmunohistochemical biomarkersImmunohistochemical markersManagement of patientsNovel immunohistochemical markerPosttreatment biopsiesImmunohistochemical toolsDisease progressionCorrect diagnosisClinical scenariosNeoplasmsPatient careLiterature searchRelevant biomarkersBiomarkersImmunohistochemistryMolecular biomarkersScientific literature searchMarkersArchival samplesOriginal articlesMolecular eraCurrent eraPatientsBiopsy
2022
Peripheral Blood Involvement at Staging in Patients With Aggressive Peripheral T-Cell Lymphoma
Avery J, Chandhok N, Rainey C, Torres R, Huntington S, Isufi I, Seropian S, Xu ML, Foss F. Peripheral Blood Involvement at Staging in Patients With Aggressive Peripheral T-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2022, 22: 680-689. PMID: 35568635, DOI: 10.1016/j.clml.2022.04.019.Peer-Reviewed Original ResearchMeSH KeywordsFlow CytometryHumansLymphoma, T-CellLymphoma, T-Cell, PeripheralPrognosisRetrospective StudiesConceptsPeripheral T-cell lymphomaT-cell lymphomaBone marrow involvementBlood involvementFlow cytometryMarrow involvementNodal subtypesAggressive peripheral T-cell lymphomaNodal T-cell lymphomasNegative flow cytometryPeripheral blood involvementPositive flow cytometryMalignant T cellsMalignant tumor cellsMedian PFSTime ofdiagnosisOverall survivalLymph nodesPoor outcomeDisease stagePeripheral bloodT cellsPrognostic measuresRare subgroupLymphoma
2021
Role of MBD3-SOX2 axis in residual myeloma following pomalidomide
Verma R, Branagan AR, Xu ML, Flavell RA, Dhodapkar KM, Dhodapkar MV. Role of MBD3-SOX2 axis in residual myeloma following pomalidomide. Leukemia 2021, 35: 3319-3323. PMID: 33603141, PMCID: PMC8371090, DOI: 10.1038/s41375-021-01145-0.Peer-Reviewed Original Research
2019
ALCL by any other name: the many facets of anaplastic large cell lymphoma
Irshaid L, Xu ML. ALCL by any other name: the many facets of anaplastic large cell lymphoma. Pathology 2019, 52: 100-110. PMID: 31706671, DOI: 10.1016/j.pathol.2019.09.007.Peer-Reviewed Original ResearchConceptsAnaplastic large cell lymphomaAnaplastic lymphoma kinaseALK gene translocationALK(-) ALCLLarge cell lymphomaALK gene rearrangementVariable prognosisFavorable prognosisCell lymphomaGene rearrangementsNon-Hodgkin T-cell lymphomaExtent of diseaseLarge lymphoma cellsT-cell lymphomaGene translocationSpecific gene rearrangementsPatient demographicsIntermediate prognosisDismal prognosisImmunohistochemical phenotypeClinical behaviorFavorable outcomeDifferential diagnosisImplant placementSkin lesionsProapoptotic protein BIM as a novel prognostic marker in mantle cell lymphoma
Wang JD, Katz SG, Morgan EA, Yang DT, Pan X, Xu ML. Proapoptotic protein BIM as a novel prognostic marker in mantle cell lymphoma. Human Pathology 2019, 93: 54-64. PMID: 31425695, PMCID: PMC7038910, DOI: 10.1016/j.humpath.2019.08.008.Peer-Reviewed Original ResearchConceptsMantle cell lymphomaCell lymphomaAnn Arbor stage IIINovel independent prognostic factorAggressive B-cell lymphomasHigh Bim expressionAverage patient ageBim expressionIndependent prognostic factorLarge academic medical centerKi-67 indexNovel prognostic markerB-cell lymphomaAcademic medical centerCyclin D1 overexpressionHuman mantle cell lymphomaMCL cohortMIPI scoreProgressive diseaseComplete responseOverall survivalPatient agePrognostic factorsTumor cell survivalFemale ratioHistiocytic and Dendritic Cell Neoplasms
Pan Z, Xu ML. Histiocytic and Dendritic Cell Neoplasms. Surgical Pathology Clinics 2019, 12: 805-829. PMID: 31352989, DOI: 10.1016/j.path.2019.03.013.Peer-Reviewed Original ResearchConceptsDendritic cell neoplasmClinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms
Patel SS, Ho C, Ptashkin RN, Sadigh S, Bagg A, Geyer JT, Xu ML, Prebet T, Mason EF, Seegmiller AC, Morgan EA, Steensma DP, Winer ES, Wong WJ, Hasserjian RP, Weinberg OK. Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms. Blood Advances 2019, 3: 1540-1545. PMID: 31085507, PMCID: PMC6517660, DOI: 10.1182/bloodadvances.2019000090.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overDNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3AFemaleHumansMaleMiddle AgedMutationMyelodysplastic SyndromesNuclear ProteinsNucleophosminPrognosisProportional Hazards ModelsProtein Tyrosine Phosphatase, Non-Receptor Type 11Survival RateTumor Suppressor Protein p53ConceptsMyelodysplastic syndromeMyeloid neoplasmsDe novo acute myeloid leukemia (AML) patientsNovo acute myeloid leukemia patientsAcute myeloid leukemia patientsBone marrow blastsAggressive clinical courseStem cell transplantLimited case seriesShorter overall survivalMyeloid leukemia patientsIntensive therapeutic regimensTotal mutation countsMarrow blastsOverall survivalClinical courseCase seriesCell transplantMultivariable analysisTherapeutic regimensLeukemia patientsLarge cohortYounger agePatientsNormal karyotype